Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma Clinical Trial
Official title:
A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
| Verified date | April 2024 |
| Source | Hoffmann-La Roche |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic G/GEJ cancer (hereafter referred to as gastric cancer) and esophageal cancer. Two cohorts of patients with gastric cancer have been enrolled in parallel in this study: the second-line (2L) Gastric Cancer Cohort consists of patients with gastric cancer who have progressed after receiving a platinum-containing or fluoropyrimide-containing chemotherapy regimen in the first-line setting, and the first-line (1L) Gastric Cancer Cohort consists of patients with gastric cancer who have not received prior chemotherapy in this setting. In each cohort, eligible patients will be assigned to one of several treatment arms. Additionally, a cohort of patients with esophageal cancer who have not received prior systemic treatment for their disease will be enrolled in this study. Eligible patients will be randomized to chemotherapy or the combination of chemotherapy with checkpoint inhibitor immunotherapy.
| Status | Active, not recruiting |
| Enrollment | 410 |
| Est. completion date | April 30, 2025 |
| Est. primary completion date | August 24, 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: Gastric Cancer Cohorts Inclusion Criteria: - Age >/= 18 years; - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; - Life expectancy >/= 3 months, as determined by the investigator; - Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma of gastric or gastroesophageal junction; (for the 1L Gastric Cancer Cohort: no prior systemic therapy for the locally advanced or metastatic disease; for the 2L Gastric Cancer Cohort: disease progression during or following a first-line platinum-containing or fluoropyrimidine-containing chemotherapy regimen); - Availability of a representative tumor specimen that is suitable for determination of PD-L1 and TIGIT levels by IHC and/or additional biomarker status by means of retrospective central testing; - Only for the 1L Gastric Cancer Cohort: human epidermal growth factor receptor 2 (HER2)-negative tumors; - Measurable disease (at least one target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1); - Adequate hematologic and end organ function based on laboratory results obtained within 14 days prior to initiation of study treatment; - For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment arm; - For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm. Esophageal Cancer Cohort Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of squamous cell carcinoma or adenocarcinoma of the esophagus in locally advanced or metastatic disease; - No prior systemic treatment for esophageal cancer, with the following exception: For patients treated with chemotherapy in the locally advanced setting: occurrence of metastasis after 6 months from the last dose of chemotherapy; - For patients with adenocarcinoma: absence of HER2 expression; - Life expectancy >/=3 months as determined by the investigator; - Measurable disease per RECIST v1.1; - Adequate hematologic and end-organ function; - For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs; - For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm; - ECOG Performance Status of 0, 1, or 2. Exclusion Criteria: Exclusion criteria for the 2L Gastric Cancer Cohort: - Urinary protein is > 1 + on dipstick and the required following 24-hour urine collection shows urinary protein > 2000 mg; - Serious or non-healing wound, peptic ulcer, or bone fracture within 28 days prior to initiation of study treatment; - History of gastrointestinal perforation and/or fistulae within 6 months prior to initiation of study treatment; - Presence of a bowel obstruction, history or presence of inflammatory enteropathy, or extensive intestinal resection, Crohn disease, ulcerative colitis, or chronic diarrhea; - Uncontrolled arterial hypertension >/= 150/ >/= 90 millimeter of mercury (mmHg) despite standard medical management; - Chronic therapy with non-steroidal anti-inflammatory agents or other anti-platelet agents. Gastric Cancer Exclusion Criteria: - Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy; - Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases; - History of leptomeningeal disease; - Active or history of autoimmune disease or immune deficiency; - History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan; - Positive test for human immunodeficiency virus (HIV) at screening; - Active hepatitis B virus (HBV) or hepatitis C (HCV) infection; - Severe infection within 4 weeks prior to initiation of study treatment; - Significant cardiovascular disease; - Significant bleeding disorder; - Prior allogeneic stem cell or solid organ transplantation; - Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study; - Treatment with anticoagulation with warfarin, low-molecular-weight heparin, or similar agents for therapeutic purposes; - History of malignancy other than gastric or gastroesophageal junction carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death; - Known allergy or hypersensitivity to any of the study drugs or their excipients. Esophageal Cancer Cohort Exclusion Criteria: - High risk for developing esophageal fistula by clinical assessment or imaging; - Symptomatic, untreated, or actively progressing central nervous system (CNS) Metastases; - Positive EBV viral capsid antigen IgM test at screening; - History of leptomeningeal disease; - Active or history of autoimmune disease or immune deficiency; - History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan; - Active tuberculosis; - Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina; - History of malignancy other than esophageal cancer within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death; - Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab or within 90 days after the final dose of tiragolumab. |
| Country | Name | City | State |
|---|---|---|---|
| Australia | Blacktown Hospital | Blacktown | New South Wales |
| Australia | Monash Medical Centre-Moorabbin Campus | Clayton | Victoria |
| Australia | Peter MacCallum Cancer Centre; Medical Oncology | Melbourne | Victoria |
| Israel | Ben-Gurion University of the Negev - Soroka University Medical Center | Beer Sheva | |
| Israel | Rambam Health Care Campus; Oncology | Haifa | |
| Israel | Hadassah University Medical Center | Jerusalem | |
| Israel | Rabin MC; Davidof Center - Oncology Institute | Petach Tikva | |
| Israel | Sourasky Medical Centre | Tel-Aviv | |
| Korea, Republic of | Yonsei University College of Medicine (YUCM)-Yonsei Cancer Center; Cancer Metastasis Research Center | Seodaemun-Gu | |
| Korea, Republic of | Seoul National University Bundang Hospital | Seongnam-si | |
| Korea, Republic of | Korea University Anam Hospital | Seoul | |
| Korea, Republic of | Samsung Medical Center | Seoul | |
| Korea, Republic of | Seoul National University Hospital (SNUH) - Medical Oncology Center | Seoul | |
| Korea, Republic of | University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC) | Songpa-gu | |
| Korea, Republic of | The Catholic University of Korea St. Vincent's Hospital | Suwon-si | |
| Spain | Hospital Universitari Vall dHebron; Oncology | Barcelona | |
| Spain | Universidad de Navarra - Clinica Universitaria de Navarra (CUN) | Pamplona | Navarra |
| Taiwan | National Cheng Kung University Hospital | Tainan | |
| Taiwan | Taipei Veterans General Hospital | Taipei City | |
| Taiwan | National Taiwan University Hospital (NTUH) - Cancer Research Center | Zhongzheng Dist. | |
| United Kingdom | Beatson West of Scotland Cancer Centre | Glasgow | |
| United Kingdom | Barts and The London School of Medicine and Dentistry - Barts Cancer Institute (BCI)-CECM | London | |
| United Kingdom | The Royal Marsden | London | |
| United Kingdom | The Christie NHS Foundation Trust | Manchester | |
| United Kingdom | The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton | Sutton | |
| United States | Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago | Illinois |
| United States | The University of Texas MD Anderson Cancer Center | Houston | Texas |
| United States | University of Kentucky | Lexington | Kentucky |
| United States | UCLA Jonsson Comprehensive Cancer Center | Los Angeles | California |
| United States | Uni of Southern California; Norris Comprehensive Cancer Ctr | Los Angeles | California |
| United States | Froedtert and The Medical College of Wisconsin | Milwaukee | Wisconsin |
| United States | Tennessee Oncology - Nashville | Nashville | Tennessee |
| United States | Columbia University Medical Center | New York | New York |
| United States | Memorial Sloan Kettering Cancer Center | New York | New York |
| United States | Mayo Clinic - Rochester; Breast Cancer Center | Rochester | Minnesota |
| United States | Mayo Clinic Cancer Center | Scottsdale | Arizona |
| Lead Sponsor | Collaborator |
|---|---|
| Hoffmann-La Roche | BioLineRx, Ltd., Halozyme Therapeutics |
United States, Australia, Israel, Korea, Republic of, Spain, Taiwan, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of Participants With Objective Response, as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) | From Randomization until disease progression or loss of clinical benefit (up to approximately 3-6 years) | ||
| Primary | Percentage of Participants with Adverse Events (AEs) | From first study treatment administration until 30 days after the last dose or until initiation of new systemic anti-cancer therapy, whichever occurs first (up to approximately 3-6 years) | ||
| Primary | For Arm 1L-A : Percentage of Participants with Serious and Non-serious Treatment-related AEs | During the safety run-in phase up to 28 days | ||
| Secondary | Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1 | From randomization up to the first occurrence of disease (up to approximately 3-6 years) | ||
| Secondary | Overall Survival (OS) | From randomization up to death from any cause (up to approximately 3-6 years) | ||
| Secondary | Percentage of Participants Who Are Alive at Month 6 and at Month 12 | Month 6, Month 12 | ||
| Secondary | Duration of Response, as Determined by Investigator According to RECIST v1.1 | From the date of first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 3-6 years) | ||
| Secondary | Percentage of Participants With Disease Control, as Determined by the Investigator per RECIST v1.1 | From randomization until disease progression or loss of clinical benefit (up to approximately 3-6 years) | ||
| Secondary | Serum Concentration of Atezolizumab | Pre-infusion (0 hour [hr]), 30 minutes (min) post-infusion (infusion=60 min) on Day 1 of Cycle 1; pre-infusion (0 hr) on Day 1 of Cycles 2, 3, 4, 8, 12, 16 (each cycle=28 days); 30 days and 120 days after last dose (up to approximately 3-6 years) | ||
| Secondary | Plasma Concentration of Cobimetinib | Prior to cobimetinib dose, 2-4 hr after cobimetinib dose on Day 15 of Cycle 1 (cycle length=28 days) | ||
| Secondary | Plasma Concentration of PEGPH20 | Pre-infusion (0 hr), 5 min and 1-3 hrs post infusion (infusion duration=10-12 min) on Day 1 of Cycle 1; pre-infusion (0 hr) on Days 8 and 15 of Cycle 1, Day 1 of Cycles 3, 4, 8, 12, 16; pre-infusion (0 hr) and 5 min post-infusion on Day 1 of Cycle 2 (each cycle=21 days); 30 days and 120 days after last dose (up to approximately 3-6 years) | Pre-infusion (0 hr) on Day 1 of Cycle 1 up to 30 days and 120 days after last dose (up to approximately 3-6 years) (Detailed timeframe is provided in outcome measure description) | |
| Secondary | Plasma Concentration of BL-8040 | Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Day 1 of Cycle 1); 1 hr post-dose on Days 1, 5 of priming period; pre-dose (0 hr), 1 hour post-dose on Day 15 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 8, 12, 16; pre-dose (0 hr) on Day 1 of Cycle 20 and every 4 cycles thereafter (each cycle=21 days) (up to approximately 3-6 years); 30 days after last dose (up to approximately 3-6 years) | Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Day 1 of Cycle 1) up to 30 days after last dose (up to approximately 3-6 years) (Detailed timeframe is provided in outcome measure description) | |
| Secondary | Plasma Concentration of Linagliptin | 2 hr postdose oral linagliptin on Day 1 of Cycle 1, prior to atezolizumab infusion and predose oral linagliptin on Day 15 of Cycle 1 as well as on Day 1 of Cycles 2, 3, and 4 | ||
| Secondary | Percentage of Participants With Anti-Drug Antibody (ADA) to Atezolizumab | Pre-infusion (0 hr) on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16 (each cycle=28 days); 30 days and 120 days after last dose (up to approximately 3-6 years) | ||
| Secondary | Percentage of Participants With ADA to PEGPH20 | Pre-infusion (0 hr) on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16 (each cycle=21 days); 30 days and 120 days after last dose (up to approximately 3-6 years) | ||
| Secondary | Percentage of Participants With ADA to BL-8040 | Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Cycle 1 Day 1), Day 15 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 8, 12, 16, 20 and every 4 cycles thereafter (each cycle=21 days) (up to approximately 3-6 years); 30 days after last dose (up to approximately 3-6 years) | Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Day 1 of Cycle 1) up to 30 days after last dose (up to approximately 3-6 years) (Detailed timeframe is provided in outcome measure description) |